BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Têtu B, Lindberg J, Egevad L, Grönberg H, Ross-adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology 2017;72:22-31. [DOI: 10.1016/j.eururo.2016.10.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol 2020;38:1474-94. [PMID: 31829902 DOI: 10.1200/JCO.19.02768] [Cited by in Crossref: 46] [Cited by in F6Publishing: 19] [Article Influence: 15.3] [Reference Citation Analysis]
2 Bandini M, Fossati N, Briganti A. Nomograms in urologic oncology, advantages and disadvantages. Current Opinion in Urology 2019;29:42-51. [DOI: 10.1097/mou.0000000000000541] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
3 Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun 2020;11:737. [PMID: 32024819 DOI: 10.1038/s41467-019-14052-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
4 Livingstone J, Shiah YJ, Yamaguchi TN, Heisler LE, Huang V, Lesurf R, Gebo T, Carlin B, Eng S, Drysdale E, Green J, van der Kwast T, Bristow RG, Fraser M, Boutros PC. The telomere length landscape of prostate cancer. Nat Commun 2021;12:6893. [PMID: 34824250 DOI: 10.1038/s41467-021-27223-6] [Reference Citation Analysis]
5 Khoo A, Liu LY, Nyalwidhe JO, Semmes OJ, Vesprini D, Downes MR, Boutros PC, Liu SK, Kislinger T. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nat Rev Urol 2021. [PMID: 34453155 DOI: 10.1038/s41585-021-00500-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chua ML, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJ, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG. A Prostate Cancer “ Nimbosus ”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology 2017;72:665-74. [DOI: 10.1016/j.eururo.2017.04.034] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 18.0] [Reference Citation Analysis]
7 Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A. Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. Front Genet 2020;11:550894. [PMID: 33324443 DOI: 10.3389/fgene.2020.550894] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tang M, Bolderson E, O'Byrne KJ, Richard DJ. Tumor Hypoxia Drives Genomic Instability. Front Cell Dev Biol 2021;9:626229. [PMID: 33796526 DOI: 10.3389/fcell.2021.626229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. Eur Urol Oncol 2019;2:1-11. [PMID: 30929837 DOI: 10.1016/j.euo.2018.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
10 Fraser M, Rouette A. Prostate Cancer Genomic Subtypes. Adv Exp Med Biol 2019;1210:87-110. [PMID: 31900906 DOI: 10.1007/978-3-030-32656-2_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Brastianos HC, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage M, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. Eur Urol Oncol 2020:S2588-9311(20)30083-3. [PMID: 32605887 DOI: 10.1016/j.euo.2020.06.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Sendorek DH, Lalonde E, Yao CQ, Sabelnykova VY, Bristow RG, Boutros PC. NanoStringNormCNV: pre-processing of NanoString CNV data. Bioinformatics 2018;34:1034-6. [PMID: 29112706 DOI: 10.1093/bioinformatics/btx707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua ML, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, Salcedo A, Houlahan KE, Li CH, Huang V, Fraser M, van der Kwast T, Morris QD, Bristow RG, Boutros PC. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell 2018;173:1003-1013.e15. [DOI: 10.1016/j.cell.2018.03.029] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 28.3] [Reference Citation Analysis]
14 Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, Den RB, Jeffrey Karnes R, Klein E, Hoskin PJ, Freedland SJ, Lamb AD, Neal DE, Buffa FM, Bristow RG, Boutros PC, Davicioni E, Choudhury A, West CML. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 2018;31:182-9. [PMID: 29729848 DOI: 10.1016/j.ebiom.2018.04.019] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
15 Hoey C, Liu SK. Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies. Res Rep Urol 2019;11:29-42. [PMID: 30881943 DOI: 10.2147/RRU.S165625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Zhao Z, Stephan C, Weickmann S, Jung M, Kristiansen G, Jung K. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies? Int J Mol Sci 2017;18:E2023. [PMID: 28934131 DOI: 10.3390/ijms18102023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, Yao CQ, Sabelnykova VY, Fraser M, Chua MLK, van der Kwast T, Liu SK, Boutros PC, Bristow RG. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet 2019;51:308-18. [PMID: 30643250 DOI: 10.1038/s41588-018-0318-2] [Cited by in Crossref: 179] [Cited by in F6Publishing: 167] [Article Influence: 59.7] [Reference Citation Analysis]
18 Baldacchino S, Grech G. Somatic copy number aberrations in metastatic patients: The promise of liquid biopsies. Semin Cancer Biol 2020;60:302-10. [PMID: 31891778 DOI: 10.1016/j.semcancer.2019.12.014] [Reference Citation Analysis]
19 Testa U, Castelli G, Pelosi E. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel) 2019;6:E82. [PMID: 31366128 DOI: 10.3390/medicines6030082] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
20 Ryan MJ, Bose R. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Front Oncol 2019;9:1287. [PMID: 31824860 DOI: 10.3389/fonc.2019.01287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
21 Fraser M, Boutros PC, Bristow RG. A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. Eur Urol 2018;73:533-4. [PMID: 29275835 DOI: 10.1016/j.eururo.2017.11.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Lieberman HB, Rai AJ, Friedman RA, Hopkins KM, Broustas CG. Prostate cancer: unmet clinical needs and RAD9 as a candidate biomarker for patient management. Transl Cancer Res 2018;7:S651-61. [PMID: 30079300 DOI: 10.21037/tcr.2018.01.21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fraser M, Livingstone J, Wrana JL, Finelli A, He HH, van der Kwast T, Zlotta AR, Bristow RG, Boutros PC. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nat Commun 2021;12:6248. [PMID: 34716314 DOI: 10.1038/s41467-021-26489-0] [Reference Citation Analysis]
24 Rebello RJ, Bristow RG. Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features. Clin Oncol (R Coll Radiol) 2020;32:298-302. [PMID: 32147317 DOI: 10.1016/j.clon.2019.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]